flt201
Gene therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Apr 15, 2022 (NCT05324943)
Timeline
Indications
Studied for
Mechanism of action
- Beta-glucocerebrosidaseSupplementation
GBA supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07223944 | Phase 3 | Jul 1, 2026 | Spur Therapeutics |
| NCT06545136 | Phase 1/Phase 2 (Phase 2) | May 13, 2024 | Spur Therapeutics |
| NCT05324943 | Phase 1/Phase 2 (Phase 2) | Apr 15, 2022 | Freeline Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Spur Therapeutics | For profit | 2 | 2 | 2 | 2024 |
| Freeline Therapeutics | For profit | 1 | 1 | 1 | 2022 |
2 organizations
Page 1 / 1